Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2017 · 10-Q
Revenue$4.20M$4.20M+26.7% vs Q3 2016 Net Income-$3.40M-$3.40MN/M vs Q3 2016 EPS Diluted-$0.15-$0.15N/M vs Q3 2016 Gross Profit$2,133,000+45.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,312,000N/M Margins · derivedGross margin50.8%+6.4 pt vs Q3 2016
Operating margin-73.7%+122.0 pt vs Q3 2016
Net margin-80.9%+160.4 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 13, 2017 · 44 d after period end